Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant

The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hematopoietic Stem Cell Transplantation Graft vs Host Disease Immune System Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232-5505, United States

About this study

The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease (GVHD) by determining the qualitative and quantitative changes in T regulatory cells throughout the transplant process. Their understanding of this can lead to new treatment strategies and improved clinical therapeutic implications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions

Exclusion criteria

Patients < 18 or > 70 years old undergoing either autologous transplant or allogeneic transplant

Sponsors and collaborators

Lead sponsor

Vanderbilt University

Other

Registry information

Official study title

Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)

Important dates

Study start: 2003
Study completion: 2008
First posted: Sep 15, 2005
Registry last updated: Dec 15, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed